Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: A retrospective database analysis

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Toth, Peter P ^a,b,c   Zarotsky, Victoria ^d   Sullivan, Jane M ^d   Laitinen, Dave ^e  

^a Sterling Rock Falls Clinic ^*  (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d i3 Innovus   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; CERIVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DATA BASE; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MONOTHERAPY; RETROSPECTIVE STUDY; AGED; BLOOD; CORONARY ARTERY DISEASE; FACTUAL DATABASE; HEALTH INSURANCE; MIDDLE AGED; PRACTICE GUIDELINE; RISK FACTOR; UNITED STATES;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES; UNITED STATES;

EID: 67650074103     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-26     Document Type: Article

References (33)

1. Moss SE Klein R Klein BE Cause-specific mortality in a population-based study of diabetes Am J Public Health 1991, 81:1158-1162. 1405646 1951827 10.2105/AJPH.81.9.1158
2. Huxley R Barzi F Woodward M Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies BMJ 2006, 332:73-78. 1326926 16371403 10.1136/ bmj.38678.389583.7C
3. Grundy SM Brewer HB Jr Cleeman JI Smith SC Jr Lenfant C For the Conference Participants. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 2004, 109:433-438. 10.1161/01.CIR.0000111245.75752.C6 14744958
4. Davidson MH Toth PP Comparative effects of lipid-lowering therapies Prog Cardiovasc Dis 2004, 47:73-104. 10.1016/j.pcad.2004.04.007 15586350
5. Hoang KC Ghandehari H Lopez VA Barboza MG Wong ND Global coronary heart disease risk assessment of U.S. persons with the metabolic syndrome Diabetes Care 2008, 31(7):1405-1409. 10.2337/dc07-2087 18375418
6. Best JD O'Neal DN Diabetic dyslipidaemia: Current treatment recommendations Drugs 2000, 59:1101-1111. 10.2165/ 00003495-200059050-00006 10852642
7. Ito MK Advances in the understanding and management of dyslipidemia: using niacin-based therapies Am J Health Syst Pharm 2003, 60(13 Suppl 2):S15-S21. 12901026
8. Bestermann W Houston MC Basile J Egan B Ferrario CM Lackland D Hawkins RG Reed J Rogers P Wise D Moore MA Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: Treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome Am J Med Sci 2005, 329:292-305. 10.1097/ 00000441-200506000-00009 15958871
9. Rubins HB Robins SJ Collins D Iranmanesh A Wilt TJ Mann D Mayo-Smith M Faas FH Elam MB Rutan GH Department of Veterans Affairs HDL Intervention Trial Study Group Distribution of lipids in 8,500 men with coronary artery disease Am J Cardiol 1995, 75:1196-1201. 10.1016/ S0002-9149(99)80761-9 7778538
10. Genest JJ McNamara JR Salem DN Schaefer EJ Prevalence of risk factors in men with premature coronary artery disease Am J Cardiol 1991, 67:1185-1189. 10.1016/0002-9149(91)90924-A 2035438
11. Pekkanen J Linn S Heiss G Suchindran CM Leon A Rifkind BM Tyroler HA Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease N Engl J Med 1990, 322:1700-1707. 2342536
12. Gordon DJ Rifkind BM High-density lipoprotein - the clinical implications of recent studies N Engl J Med 1989, 321:1311-316. 2677733
13. Goldbourt U Yaari S Medalie JH Isolated low HDL-C cholesterol as a risk factor for coronary heart disease mortality: A 21-year follow-up of 8000 men Arterioscler Thromb Vasc Biol 1997, 17:107-113. 9012644
14. Rubins HB Robins SJ Collins D Fye CL Anderson JW Elam MB Faas FH Linares E Schaefer EJ Schectman G Wilt TJ Wittes J Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 1999, 341:410-418. 10.1056/NEJM199908053410604 10438259
15. Miller M Cannon CP Murphy SA Qin J Ray KK Braunwald E PROVE ITTIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol. 2008, 51(7):724-730. 10.1016/ j.jacc.2007.10.038 18279736
16. Tenkanen L Manttari M Manninen V Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study Circulation 1995, 92:1779-1785. 7671361.
17. The BIP Study Group Secondary prevention by raising HDL-C-cholesterol and reducing triglycerides in patients with coronary disease: The Bezafibrate Infarction Prevention (BIP) Study Circulation 2000, 102:21-27. 10880410
18. Buse JB Ginsberg HN Bakris GL Clark NG Costa F Eckel R American Heart Association; American Diabetes Association Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association Circulation 2007, 115(1):114-26. 10.1161/ CIRCULATIONAHA.106.179294 17192512
19. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Circulation 2002, 106:3144-3421.
20. Vega GL Ma PT Cater NB Filipchuk N Meguro S Garcia-Garcia AB Fonseca V Gerstein HC Grundy S Nesto RW Pignone MP Plutzky J Porte D Redberg R Stitzel KF Stone NJ American Heart Association; American Diabetes Association Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome Am J Cardiol 2003, 91:956-960. 10.1016/S0002-9149(03)00111-5 12686335
21. Wagner AM Jorba O Bonet R Ordonez-Llanos J Perez A Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia J Clin Endocrinol Metab 2003, 88:3212-3217. 10.1210/jc.2003-030153 12843167
22. Derosa G Cicero AE Bertone G Piccinni MN Ciccarelli L Roggeri DE Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: A 12-month, randomized, double blind, controlled trial Clin Ther 2004, 26:1599-1607. 10.1016/j.clinthera.2004.10.008 15598476
23. Wake Forest University School of Medicine Public Health Sciences Department. ACCORD Trial Website http://www.accordtrial.org/web/public/ index.cfm
24. Keevil JH Cullen MW Gangnon R McBride PE Stein JH Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: Data from National Health and Nutrition Examination Survey 1999 to 2002 Circulation 2007, 115:1363-1370. 10.1161/CIRCULATIONAHA.106.645473 17353444
25. Howell EE Wright SM Bush DE Chandra-Strobos N Henrikson CA Insufficient treatment of hypercholesterolemia among patients hospitalized with chest pain Clin Cardiol 2006, 29:259-262. 10.1002/clc.4960290607 16796076
26. Waters DD What the statin trials have taught us Am J Cardiol 2006, 98:129-134. 10.1016/j.amjcard.2006.01.066 16784935
27. Grant RW Meigs JB Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: An unmet challenge for cardiovascular risk reduction Diabetes Care 2007, 30:479-484. 10.2337/ dc06-1961 17327308
28. Alsheikh-Ali AA Lin JL Abourjaily P Ahearn D Kuvin JT Karas RH Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol Am J Cardiol 2007, 100:1499-1501. 10.1016/j.amjcard.2007.06.058 17996508
29. Klingman D Williams SA Benner JS Smith TW Ahn J O'Donnell JC Gauging the treatment gap in dyslipidemia: Findings from the 1999-2000 National Health and Nutrition Examination Survey Am Heart J 2005, 150:595-601. 10.1016/j.ahj.2004.09.039 16169347
30. Davidson MH Differences between clinical trial efficacy and real-world effectiveness Am J Manag Care 2006, 12(15 Suppl):S405-S411. 17112328
31. Guthrie RM How safe is aggressive statin therapy? Prog Cardiovasc Nurs 2006, 21:140-145. 10.1111/j.0889-7204.2006.05616.x 16957460
32. Pearlman BL The new cholesterol guidelines. Applying them in clinical practice Postgrad Med 2002, 112:13-16. 10.3810/pgm.2002.08.1269 12198751
33. Stacy TA Egger A Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs J Manag Care Pharm 2006, 12:745-751. 17249907